公开(公告)号：US08968779B2

公开(公告)日：2015-03-03

申请号：US13704345

申请日：2011-06-15

申请人： Kentaro Fujinaga ,  Susumu Maruo ,  Hideaki Nakamura ,  Kenji Sunagawa ,  Tsutomu Mochizuki ,  Michiharu Kageyama

发明人： Kentaro Fujinaga ,  Susumu Maruo ,  Hideaki Nakamura ,  Kenji Sunagawa ,  Tsutomu Mochizuki ,  Michiharu Kageyama

IPC分类号： A61K9/24 ,  A61K9/28 ,  A61K31/426 ,  A61K9/20

CPC分类号： A61K9/2866 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/426

摘要： Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucleus contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and the outer layer contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and a gel-forming water-soluble polymer that is in an amount of 16 (w/w) % or more relative to the weight of the outer layer.

摘要翻译： 公开了一种控制释放有核的片剂，其由内核和覆盖内核的外层组成，并且能够维持2-（3-氰基-4-异丁氧基苯基）-4-甲基-5-噻唑甲酸 血液中的酸长时间达到一定值或更高。 控释片的特征在于内核含有2-（3-氰基-4-异丁氧基苯基）-4-甲基-5-噻唑甲酸，外层含有2-（3-氰基-4-异丁氧基苯基） - 4-甲基-5-噻唑甲酸和相对于外层重量为16（w / w）％以上的凝胶形成性水溶性聚合物。

公开(公告)号：US20130089609A1

公开(公告)日：2013-04-11

申请号：US13704345

申请日：2011-06-15

申请人： Kentaro Fujinaga ,  Susumu Maruo ,  Hideaki Nakamura ,  Kenji Sunagawa ,  Tsutomu Mochizuki ,  Michiharu Kageyama

发明人： Kentaro Fujinaga ,  Susumu Maruo ,  Hideaki Nakamura ,  Kenji Sunagawa ,  Tsutomu Mochizuki ,  Michiharu Kageyama

IPC分类号： A61K9/28

CPC分类号： A61K9/2866 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/426

摘要： Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucleus contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and the outer layer contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and a gel-forming water-soluble polymer that is in an amount of 16 (w/w) % or more relative to the weight of the outer layer.

摘要翻译： 公开了一种控制释放有核的片剂，其由内核和覆盖内核的外层组成，并且能够维持2-（3-氰基-4-异丁氧基苯基）-4-甲基-5-噻唑甲酸 血液中的酸长时间达到一定值或更高。 控释片的特征在于内核含有2-（3-氰基-4-异丁氧基苯基）-4-甲基-5-噻唑甲酸，外层含有2-（3-氰基-4-异丁氧基苯基） - 4-甲基-5-噻唑甲酸和相对于外层重量为16（w / w）％以上的凝胶形成性水溶性聚合物。